 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...56789101112131415...2223» |
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial termination, Monotherapy: REVERT: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (clinicaltrials.gov) - Aug 31, 2021
P2, N=22, Terminated, Sponsor: MedSIR
N=60 --> 22 | Trial completion date: Sep 2021 --> Mar 2021 | Recruiting --> Terminated; Slow recruitment rate
- |||| Halaven (eribulin mesylate) / Eisai
Trial completion: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Aug 24, 2021
P1b/2, N=258, Completed, Sponsor: Eisai Inc.
N=60 --> 22 | Trial completion date: Sep 2021 --> Mar 2021 | Recruiting --> Terminated; Slow recruitment rate Active, not recruiting --> Completed
- | Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial initiation date, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - Aug 19, 2021
P1/2, N=41, Not yet recruiting, Sponsor: Colette Shen
Active, not recruiting --> Completed Initiation date: Feb 2021 --> Aug 2021
- | Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Ono Pharma
Trial primary completion date: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Aug 18, 2021
P1, N=24, Recruiting, Sponsor: Montefiore Medical Center
Initiation date: Feb 2021 --> Aug 2021 Trial primary completion date: Jul 2021 --> Feb 2022
- | Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Scalp Cooling in MBC (clinicaltrials.gov) - Aug 3, 2021
P2, N=120, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors (clinicaltrials.gov) - Aug 2, 2021
P1/2, N=40, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Jul 2021 --> Feb 2022 Recruiting --> Completed | N=111 --> 40 | Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, IO biomarker: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Jul 27, 2021
P2, N=46, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting --> Completed | N=111 --> 40 | Trial completion date: Sep 2021 --> May 2021 | Trial primary completion date: Sep 2021 --> May 2021 Recruiting --> Active, not recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Jul 16, 2021
P2, N=22, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=32 --> 22
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 8, 2021
P1/2, N=30, Active, not recruiting, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting | N=32 --> 22 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment change: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 28, 2021
P1/2, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=106 --> 18
- ||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial completion date: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Jun 24, 2021
P3, N=543, Active, not recruiting, Sponsor: Gilead Sciences
N=106 --> 18 Trial completion date: May 2023 --> Dec 2023
- ||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Jun 8, 2021
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Trial completion date: May 2023 --> Dec 2023 Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Halaven (eribulin mesylate) / Eisai
New P2 trial, Combination therapy, Metastases: TEMPLATE: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer?A Prospective Multiple-center Phase II Study (clinicaltrials.gov) - Jun 3, 2021
P2, N=265, Not yet recruiting, Sponsor: Fudan University
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - May 12, 2021
P1, N=50, Recruiting, Sponsor: Athenex, Inc.
Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Mar 2023 Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Aug 2021
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment closed: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - May 10, 2021
P2, N=57, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jul 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Aug 2021 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Apr 26, 2021
P=N/A, N=201, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Recruiting --> Active, not recruiting N=120 --> 201
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment closed, Enrollment change: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Apr 23, 2021
P3, N=543, Active, not recruiting, Sponsor: Immunomedics, Inc.
N=120 --> 201 Recruiting --> Active, not recruiting | N=400 --> 543
- || Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: IRENE: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=400, Recruiting, Sponsor: Eisai GmbH
Recruiting --> Active, not recruiting | N=400 --> 543 Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Apr 22, 2021
P2, N=37, Active, not recruiting, Sponsor: Yonsei University
Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Sep 2021 --> Apr 2022 Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Nov 2021 | Trial primary completion date: Mar 2021 --> Nov 2021
- ||||||| Talzenna (talazoparib) / Pfizer
Trial completion, Metastases: A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (clinicaltrials.gov) - Apr 19, 2021
P3, N=431, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial completion date: Mar 2021 --> Nov 2021 | Trial primary completion date: Mar 2021 --> Nov 2021 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: Loreline Study: Characterization of Long Responders Under Eribuline (clinicaltrials.gov) - Apr 5, 2021
P=N/A, N=97, Completed, Sponsor: Centre Jean Perrin
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | balixafortide (POL 6326) / Spexis, Halaven (eribulin mesylate) / Eisai
New P1/2 trial: POLTER: POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Apr 1, 2021
P1/2, N=168, Not yet recruiting, Sponsor: MedSIR
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Mar 12, 2021
P2, N=88, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2020 --> Aug 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Mar 10, 2021
P1, N=27, Completed, Sponsor: City of Hope Medical Center
Trial primary completion date: Aug 2020 --> Aug 2021 Active, not recruiting --> Completed | N=45 --> 27
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Mar 10, 2021
P1, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=45 --> 27 Trial completion date: Sep 2019 --> Dec 2021
- | Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date: Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) - Mar 9, 2021
P2, N=40, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Trial completion date: Sep 2019 --> Dec 2021 Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Metastases: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment (clinicaltrials.gov) - Mar 4, 2021
P4, N=200, Completed, Sponsor: Oncologia Medica dell'Ospedale Fatebenefratelli
Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial completion: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Mar 4, 2021
P2, N=44, Completed, Sponsor: MedSIR
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2020 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Mar 3, 2021
P2, N=32, Active, not recruiting, Sponsor: Virginia G. Kaklamani
Active, not recruiting --> Completed Trial completion date: Dec 2020 --> Nov 2021
- | Halaven (eribulin mesylate) / Eisai
Enrollment open: SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov) - Mar 1, 2021
P3, N=465, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Nov 2021 Not yet recruiting --> Recruiting
- | Xpovio (selinexor) / Karyopharm
Enrollment change, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Feb 21, 2021
P1, N=390, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=247 --> 390
- ||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Feb 17, 2021
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
N=247 --> 390 Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Aug 2022 --> Dec 2022
- | Trial completion date, Trial primary completion date: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 9, 2021
P1, N=24, Recruiting, Sponsor: Presage Biosciences
Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: Aug 2022 --> Dec 2022 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 8, 2021
P2, N=100, Recruiting, Sponsor: Fudan University
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Feb 8, 2021
P2, N=78, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Metastases: Eribulin in mTNBC Patients (clinicaltrials.gov) - Feb 3, 2021
P=N/A, N=208, Completed, Sponsor: Fudan University
Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022 Active, not recruiting --> Completed | N=100 --> 208
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) - Feb 2, 2021
P2, N=16, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | N=100 --> 208 Trial primary completion date: May 2021 --> May 2022
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, BRCA Biomarker, PARP Biomarker, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Jan 26, 2021
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: May 2021 --> May 2022 Trial completion date: Dec 2020 --> Dec 2021
- | Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jan 25, 2021
P1, N=247, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2020 --> Dec 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Jan 22, 2021
P1, N=19, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Trial completion date: Dec 2020 --> Dec 2021
- || Imfinzi (durvalumab) / AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1/2 trial, Surgery: SOLARA: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (clinicaltrials.gov) - Jan 14, 2021
P1/2, N=41, Not yet recruiting, Sponsor: Colette Shen
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Jan 14, 2021
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2020 --> Dec 2021 Trial primary completion date: Jan 2021 --> Dec 2021
- ||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment closed: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Jan 11, 2021
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
Trial primary completion date: Jan 2021 --> Dec 2021 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment open, Trial completion date, Trial primary completion date: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 7, 2021
P1/2, N=106, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Trial completion date, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Jan 6, 2021
P=N/A, N=35, Recruiting, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021 Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Metastases: E-SPEC: Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer (clinicaltrials.gov) - Dec 28, 2020
P=N/A, N=120, Completed, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
New trial, Real-world evidence: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - Dec 23, 2020
P, N=80, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P2 trial, Metastases: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2020
P2, N=71, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Halaven (eribulin mesylate) / Eisai
Trial initiation date: SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov) - Dec 17, 2020
P3, N=465, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Dec 2020 --> May 2021
- || Halaven (eribulin mesylate) / Eisai, rebastinib (DCC-2036) / Ono Pharma
Enrollment change: Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (clinicaltrials.gov) - Dec 11, 2020
P1, N=24, Recruiting, Sponsor: Montefiore Medical Center
Initiation date: Dec 2020 --> May 2021 N=60 --> 24